Following intramuscular injection of a novel subunit vaccine containing a TLR4 agonist adjuvant, which immunological outcome is most likely, compared to the same vaccine without adjuvant?

💡 Explanation

The TLR4 agonist acts as an adjuvant, triggering increased co-stimulation and cytokine production. This enhanced immune activation promotes greater germinal center activity and B cell affinity maturation; therefore, a vaccine with adjuvant leads to enhanced B cell affinity maturation rather than reduced response observed without it.

• If a burn patient receives a skin graft lacking fibroblasts, which consequence follows regarding collagen?
• What happens to portal vein pressure when liver stellate cells, activated by TGF-β during cirrhosis, deposit excessive collagen in the space of Disse?
• If a patient's distal convoluted tubule and collecting duct are impermeable to water due to non-functional aquaporins, which consequence follows regarding plasma osmolality and ADH levels?
• Following mRNA vaccination against a novel influenza strain, what happens to the average antibody affinity within a germinal center over several weeks?
• Why does severe dehydration cause rapid, potentially fatal, brain cell shrinkage in elderly patients, despite the plasma osmolality initially remaining within a near-normal range?
• Why does the human body initiate shivering during hypothermia, rather than vasodilation, to restore its optimal internal temperature?